News & Features
Virginia Economic Review
Our quarterly publication, Virginia Economic Review, provides an insider look at Virginia’s economy, its diverse array of world-class companies, its amazing talent, and its stunning natural beauty, as well as insights from national thought leaders.
Filter by:
Hopewell Riverwalk
The Communities at the Forefront of Virginia’s Biopharma Push: The I95-I85 Intersection
The I95-I85 Intersection is anchored by the Tri-Cities of Petersburg (home to Civica Rx’s facility that produces a wide variety of affordable essential medicines), Hopewell, and Colonial Heights.
04.01.2026
The Urgency of Building Healthier Communities
Pam Cheng is executive vice president of global operations and IT and chief sustainability officer at AstraZeneca, which recently announced a new facility in Albemarle County — the company’s first in Virginia.
04.01.2026
The History and Future of Pharmaceutical Manufacturing in Virginia
Dave Maraldo is the senior vice president of Human Health Manufacturing Operations at Merck, one of the five largest biopharmaceutical companies in the world.
04.01.2026
Merck’s Elkton Growth From ‘Vitamin Valley’ Beginnings
Merck’s expansion at its Rockingham County site, announced in late 2025, represents the continuation of a long, mutually beneficial tenure in the Commonwealth.
Best Medical Ships Crucial Cancer Therapies Worldwide, With VEDP’s Help
Best Medical International manufactures a crucial product that helps its users battle devastating cancers. Now, with an assist from VEDP, the company is getting its products into the hands of people who desperately need them.
04.01.2026
The Investments Behind a Biopharma Hotspot
A lot changed in Virginia’s life sciences industry in the space of about a month last fall. Between Sept. 16 and Oct. 20, biopharmaceutical manufacturing giants Eli Lilly and Company, AstraZeneca, and Merck & Co.
Building a Sustainable Pharma Manufacturing Workforce
Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.



